CIB-L43

SKU: orb2944492

Description

CIB-L43 is a potent, orally bioavailable TRBP inhibitor (K_D = 4.78 nM) that suppresses oncogenic miR-21 biogenesis. This action upregulates PTEN and Smad7, blocking AKT and TGF-β pathways to inhibit hepatocellular carcinoma cell proliferation and migration in vitro.

Research Area

Cell Biology, Molecular Biology, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1082942-70-8
• MW: 304.36
• Purity: 99.64%
• Formula: C₁₅H₁₆N₂O₃S
• SMILES: O=C(O)C=1SC(=NC1C)C=2C=CC(=CC2)N3CCOCC3
• Target: PTEN,Akt,TGF-beta/Smad,DNA/RNA Synthesis
• Solubility: DMSO:5 mg/mL (16.43 mM)

Bioactivity

• Target IC50:
  TRBP-Dicer interaction:2.34 μM|miR-21 biosynthesis (HCC cells):0.66 nM (EC50)
• In Vivo:
  In hepatocellular carcinoma mouse models, CIB-L43 showed favorable pharmacokinetics, including an oral bioavailability of 53.9%.
• In Vitro:
  CIB-L43, a 2-phenylthiazole-5-carboxylic acid derivative, binds TRBP with high affinity (KD = 4.78 nM) and disrupts the TRBP-Dicer interaction (IC₅₀ = 2.34 μM). In hepatocellular carcinoma cells, CIB-L43 suppresses oncogenic miR-21 biosynthesis with nanomolar potency (EC₅₀ = 0.66 nM), upregulates tumor suppressors PTEN and Smad7, inhibits AKT and TGF-β signaling, and significantly reduces cell proliferation and migration.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CIBL43

Compound Identifiers

PubChem CID

28343014